A look at what to expect when companies report third-quarter 2025 operating results beginning in late October and extending through November.

This month I share insights into how I might temporarily downsize or exit Finch Trades positions if the market keeps melting up.

The three pivotal data readouts for plozasiran could expand the commercial opportunity beyond the 1,000-patient niche of FCS and into the 3.5 million-patient opportunity in SHTG.

A look at what to expect when companies report second-quarter 2025 operating results beginning in late July and extending through August.

A look at what to expect when companies report first-quarter 2025 operating results beginning in late April and extending through May.

Silencing mutant proteins has demonstrated promising therapeutic potential in the liver disease. Correcting mutant proteins seems even better.

The RNAi pioneer will earn $825 million upfront, plus $300 million more in the next 12 months for clinical milestones. The haul provides a cash runway into 2028.

This month I reveal my lessons from the last market bubble and correction, which influences my current strategy. I also beat you over the head as a reminder to avoid FOMO, remain disciplined, and keep your emotions separated from your money.

The business is poised for an inflection point in 2024 as it ramps multiple new products and returns to cash-flow positive operations, which has been the primary driver of Wall Street's disinterest in the stock.

Sentiment for biotech is historically low right now. Although investors are rightfully eyeing Arrowhead Pharmaceuticals' high cash burn with unease, I think the recent punishment is short-sighted.

Operating cash outflow in the first half of 2024 exceeded the annual total from 2023. That's the price to pay for an ambitious (and top-tier) pipeline.

The RNAi drug developer will effectively place a ceiling on non-core R&D expenses. The decision can help to offset fast-growing expenses in support of core cardiometabolic and lung programs.